Payment overview · 2025
General Payments
$533.85
17 reported records · 7 companies
Healthcare provider profile · identity verified
Nidavanh Klopfenstein, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · COLUMBUS, IN · NPI 1275694911
Verified facts
What the public records show
CMS Open Payments records show Nidavanh Klopfenstein, NP received $533.85 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Auvelity, Invega Sustenna, Secuado, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIVITROL as an associated drug or biological on 9533 records involving 5661 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Vivitrol by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Auvelity by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Invega Trinza by this doctor in 2024.
Noven Therapeutics, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Secuado as an associated drug or biological on 1988 records involving 1044 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Secuado by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.93 | 29.4% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $152.49 | 28.6% | 4 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $87.73 | 16.4% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $69.09 | 12.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.61 | 4.6% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $21.77 | 4.1% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $21.23 | 4.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $533.85 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $156.93 | 4 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $152.49 | 4 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $87.73 | 3 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $51.37 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $43.91 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.61 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| Secuado Normalized: secuado |
Drug | Noven Therapeutics, LLC | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 54 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 238 | exact normalized | Medicare Part D |
| Secuado secuado |
2025 | Secuado | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | VIVITROL open payments reported associated product |
CMS Open Payments — General Payments 9533 supporting records · 5661 recipient NPIs · example record 1222428584 |
Vivitrol · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
238 | 26 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Noven Therapeutics, LLC Exact reporting entity; no affiliate inference |
2025 | Secuado open payments reported associated product |
CMS Open Payments — General Payments 1988 supporting records · 1044 recipient NPIs · example record 1240398301 |
Secuado · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trazodone Hcl | Trazodone Hcl | 383 | 65 |
| Buspirone Hcl | Buspirone Hcl | 316 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 289 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 281 | 32 |
| Invega Sustenna | Paliperidone Palmitate | 238 | 26 |
| Amantadine | Amantadine Hcl | 209 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 205 | 27 |
| Bupropion Xl | Bupropion Hcl | 185 | 25 |
| Olanzapine | Olanzapine | 167 | 21 |
| Sertraline Hcl | Sertraline Hcl | 146 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 139 | 16 |
| Clonazepam | Clonazepam | 133 | 18 |
| Risperidone | Risperidone | 132 | 21 |
| Aripiprazole | Aripiprazole | 126 | 23 |
| Lamotrigine | Lamotrigine | 115 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 110 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 106 | 16 |
| Mirtazapine | Mirtazapine | 105 | 16 |
| Rexulti | Brexpiprazole | 105 | 19 |
| Trintellix | Vortioxetine Hydrobromide | 105 | 15 |
| Abilify Maintena | Aripiprazole | 99 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 97 | 13 |
| Prazosin Hcl | Prazosin Hcl | 97 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 13 |
| Paliperidone Er | Paliperidone | 88 | 14 |
| Haloperidol | Haloperidol | 80 | suppressed |
| Topiramate | Topiramate | 80 | 11 |
| Lurasidone Hcl | Lurasidone Hcl | 78 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 75 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 75 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 75 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 71 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 69 | 15 |
| Clozapine | Clozapine | 69 | suppressed |
| Quviviq | Daridorexant Hcl | 57 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 54 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 54 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 53 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 51 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 45 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 45 | suppressed |
| Austedo | Deutetrabenazine | 44 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 41 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 41 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 31 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 31 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 28 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 28 | suppressed |
| Lamotrigine Er | Lamotrigine | 28 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 28 | suppressed |
| Topiramate Er | Topiramate | 26 | suppressed |
| Gabapentin | Gabapentin | 25 | suppressed |
| Loxapine | Loxapine Succinate | 25 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 25 | suppressed |
| Austedo Xr | Deutetrabenazine | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Caplyta | Lumateperone Tosylate | 21 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 19 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 18 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Vivitrol | Naltrexone Microspheres | 16 | suppressed |
| Aristada | Aripiprazole Lauroxil | 15 | suppressed |
| Fetzima | Levomilnacipran Hcl | 15 | suppressed |
| Ingrezza | Valbenazine Tosylate | 15 | suppressed |
| Clozapine Odt | Clozapine | 14 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Secuado | Asenapine | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $533.85 · 17 records | ABBVIE INC. | ARISTADA, Auvelity, Azstarys, COBENFY, INVEGA SUSTENNA, LYBALVI, SPRAVATO, Secuado, VRAYLAR, Xelstrym | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error